JP2008526815A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526815A5 JP2008526815A5 JP2007549905A JP2007549905A JP2008526815A5 JP 2008526815 A5 JP2008526815 A5 JP 2008526815A5 JP 2007549905 A JP2007549905 A JP 2007549905A JP 2007549905 A JP2007549905 A JP 2007549905A JP 2008526815 A5 JP2008526815 A5 JP 2008526815A5
- Authority
- JP
- Japan
- Prior art keywords
- dihydrobenzimidazol
- benzimidazol
- ylideneamine
- difluorobenzyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010010904 Convulsion Diseases 0.000 claims 3
- -1 [1,3-bis (3,4-difluorobenzyl) -1,3-dihydrobenzimidazol-2-ylidene] methylamine Chemical compound 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- YEAAIIADVGBKSH-UHFFFAOYSA-N 1,3-bis[(3,4-dichlorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C(=N)N(CC=2C=C(Cl)C(Cl)=CC=2)C2=CC=CC=C21 YEAAIIADVGBKSH-UHFFFAOYSA-N 0.000 claims 1
- XWBVDMNWJUDASZ-UHFFFAOYSA-N 1,3-bis[(3,4-difluorophenyl)methyl]-5-fluorobenzimidazol-2-imine Chemical compound N=C1N(CC=2C=C(F)C(F)=CC=2)C2=CC(F)=CC=C2N1CC1=CC=C(F)C(F)=C1 XWBVDMNWJUDASZ-UHFFFAOYSA-N 0.000 claims 1
- GHCICORVEQAIHN-UHFFFAOYSA-N 1,3-bis[(3,4-difluorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=C(F)C(F)=CC=C1CN1C(=N)N(CC=2C=C(F)C(F)=CC=2)C2=CC=CC=C21 GHCICORVEQAIHN-UHFFFAOYSA-N 0.000 claims 1
- PRPVVGOVABTWIN-UHFFFAOYSA-N 1,3-bis[(3,5-difluorophenyl)methyl]benzimidazol-2-imine Chemical compound FC1=CC(F)=CC(CN2C(N(CC=3C=C(F)C=C(F)C=3)C3=CC=CC=C32)=N)=C1 PRPVVGOVABTWIN-UHFFFAOYSA-N 0.000 claims 1
- FZYLNDWXQQOELC-UHFFFAOYSA-N 1,3-bis[(4-chlorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=CC(Cl)=CC=C1CN1C(=N)N(CC=2C=CC(Cl)=CC=2)C2=CC=CC=C21 FZYLNDWXQQOELC-UHFFFAOYSA-N 0.000 claims 1
- JTFDJVUBQMWYHO-UHFFFAOYSA-N 1,3-bis[(4-fluorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=CC(F)=CC=C1CN1C(=N)N(CC=2C=CC(F)=CC=2)C2=CC=CC=C21 JTFDJVUBQMWYHO-UHFFFAOYSA-N 0.000 claims 1
- YIZUXDQFLHENGO-UHFFFAOYSA-N 1,3-bis[[3-(trifluoromethyl)phenyl]methyl]benzimidazol-2-imine Chemical compound FC(F)(F)C1=CC=CC(CN2C(N(CC=3C=C(C=CC=3)C(F)(F)F)C3=CC=CC=C32)=N)=C1 YIZUXDQFLHENGO-UHFFFAOYSA-N 0.000 claims 1
- VIEAOLWFSGPFFM-UHFFFAOYSA-N 1,3-dibenzylbenzimidazol-2-imine Chemical compound C12=CC=CC=C2N(CC=2C=CC=CC=2)C(=N)N1CC1=CC=CC=C1 VIEAOLWFSGPFFM-UHFFFAOYSA-N 0.000 claims 1
- FJJQYBQDSHUVLY-UHFFFAOYSA-N 1-(3,4-difluorophenyl)-3-[(3,4-difluorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=C(F)C(F)=CC=C1CN1C(=N)N(C=2C=C(F)C(F)=CC=2)C2=CC=CC=C21 FJJQYBQDSHUVLY-UHFFFAOYSA-N 0.000 claims 1
- YGSKVNPTXUVGRK-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-n-[4-(trifluoromethyl)phenyl]benzimidazol-2-amine Chemical compound C1=C(F)C(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1=CC=C(C(F)(F)F)C=C1 YGSKVNPTXUVGRK-UHFFFAOYSA-N 0.000 claims 1
- LAARDYYRBRIZFG-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-n-[(3,4-dichlorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC=C2N=C1NCC1=CC=C(Cl)C(Cl)=C1 LAARDYYRBRIZFG-UHFFFAOYSA-N 0.000 claims 1
- UGCVIZGMHYOEKV-UHFFFAOYSA-N 1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-n-[(3,4-difluorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=C(F)C(F)=CC=C1CNC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C(C(F)(F)F)=C1 UGCVIZGMHYOEKV-UHFFFAOYSA-N 0.000 claims 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 claims 1
- YPCHOGYWRUUMCF-UHFFFAOYSA-N 5-bromo-1,3-bis[(3,4-difluorophenyl)methyl]benzimidazol-2-imine Chemical compound C1=C(F)C(F)=CC=C1CN1C(=N)N(CC=2C=C(F)C(F)=CC=2)C2=CC(Br)=CC=C21 YPCHOGYWRUUMCF-UHFFFAOYSA-N 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000003483 hypokinetic effect Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- UKXDHSRCGYBMEP-UHFFFAOYSA-N n,1-bis[(3,4-dichlorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C(Cl)=C1 UKXDHSRCGYBMEP-UHFFFAOYSA-N 0.000 claims 1
- ORMHJEUNDBIXRO-UHFFFAOYSA-N n,1-bis[(3,4-difluorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=C(F)C(F)=CC=C1CNC1=NC2=CC=CC=C2N1CC1=CC=C(F)C(F)=C1 ORMHJEUNDBIXRO-UHFFFAOYSA-N 0.000 claims 1
- YXUWSZZABLXLKN-UHFFFAOYSA-N n,1-bis[(4-chlorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1 YXUWSZZABLXLKN-UHFFFAOYSA-N 0.000 claims 1
- JNCQVEDGQFGALE-UHFFFAOYSA-N n,1-bis[(4-fluorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=CC(F)=CC=C1CNC1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 JNCQVEDGQFGALE-UHFFFAOYSA-N 0.000 claims 1
- VGLAVFBOSNHDPO-UHFFFAOYSA-N n-(3,4-difluorophenyl)-1-[(3,4-difluorophenyl)methyl]benzimidazol-2-amine Chemical compound C1=C(F)C(F)=CC=C1CN1C2=CC=CC=C2N=C1NC1=CC=C(F)C(F)=C1 VGLAVFBOSNHDPO-UHFFFAOYSA-N 0.000 claims 1
- BBRYGOLCWUAAQS-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-1-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]benzimidazol-2-amine Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(CN2C3=CC=CC=C3N=C2NC=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 BBRYGOLCWUAAQS-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64253805P | 2005-01-11 | 2005-01-11 | |
| DKPA200500049 | 2005-01-11 | ||
| DKPA200500240 | 2005-02-16 | ||
| US65351305P | 2005-02-17 | 2005-02-17 | |
| PCT/EP2006/050108 WO2006074991A1 (en) | 2005-01-11 | 2006-01-10 | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526815A JP2008526815A (ja) | 2008-07-24 |
| JP2008526815A5 true JP2008526815A5 (https=) | 2009-02-19 |
Family
ID=36010294
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549905A Abandoned JP2008526815A (ja) | 2005-01-11 | 2006-01-10 | 低コンダクタンスのカルシウム依存性カリウムチャネルのモジュレーターとしての新規２−アミノベンゾイミダゾール誘導体及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7842817B2 (https=) |
| EP (2) | EP1838306B1 (https=) |
| JP (1) | JP2008526815A (https=) |
| AT (1) | ATE488235T1 (https=) |
| DE (1) | DE602006018255D1 (https=) |
| WO (1) | WO2006074991A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007042571A1 (en) * | 2005-10-14 | 2007-04-19 | Neurosearch A/S | Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| WO2007084728A2 (en) * | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| JP2009542602A (ja) * | 2006-07-07 | 2009-12-03 | ノイロサーチ アクティーゼルスカブ | ２−アミノベンズイミダゾール誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用 |
| US8039632B2 (en) * | 2006-11-13 | 2011-10-18 | Neurosearch A/S | 2-aminio-pyridine derivatives and their use as potassium channel modulators |
| WO2008058536A1 (en) * | 2006-11-13 | 2008-05-22 | Neurosearch A/S | Novel 4-amino-pyridine derivatives and their use as potassium channel modulators |
| US8759520B2 (en) | 2008-12-08 | 2014-06-24 | Boehringer Ingelheim International Gmbh | Compounds for treating cancer |
| WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| JP2013528635A (ja) * | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| EP2810773A1 (en) | 2013-06-05 | 2014-12-10 | Basell Poliolefine Italia S.r.l. | Butene-1 copolymer tie layer in multilayer film structures having a low seal temperature and improved hot tack |
| BR112016007065A2 (pt) | 2013-10-10 | 2017-08-01 | Basf Se | composto, composição, utilização de um composto e método para o controle da vegetação |
| WO2016077541A1 (en) * | 2014-11-12 | 2016-05-19 | The Trustees Of The University Of Pennsylvania | Novel anti-infective compounds and methods using same |
| CN104744375B (zh) * | 2015-02-10 | 2017-09-19 | 南开大学 | 一种胍类ntr1小分子拮抗剂 |
| WO2019028308A1 (en) * | 2017-08-04 | 2019-02-07 | Goldfinch Bio, Inc. | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES AND METHODS OF USE |
| EP3668841A1 (en) * | 2017-08-14 | 2020-06-24 | Acesion Pharma ApS | Substituted benzimidazoles as potassium channel inhibitors |
| ES2885179T3 (es) * | 2017-08-23 | 2021-12-13 | Acesion Pharma Aps | Derivados de bencimidazol útiles como inhibidores del canal de potasio |
| MX2020010155A (es) * | 2018-03-27 | 2021-03-25 | Univ Texas | Compuestos de ox2r. |
| CA3173733A1 (en) * | 2020-02-26 | 2021-09-02 | The Scripps Research Institute | Small molecule inhibitors of scl15a4 with anti-inflammatory activity |
| JP7853995B2 (ja) * | 2021-03-22 | 2026-04-30 | アセシオン ファーマ エイピーエス | 新規カリウムチャネル阻害剤 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3981886A (en) | 1975-01-20 | 1976-09-21 | E. R. Squibb & Sons, Inc. | Amino-benzimidazole derivatives |
| US4004016A (en) * | 1975-08-11 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Amino-benzimidazole derivatives |
| EP1091942B1 (en) * | 1998-07-02 | 2005-03-30 | Neurosearch A/S | Potassium channel blocking agents |
| US6194447B1 (en) * | 1998-07-02 | 2001-02-27 | Neurosearch A/S | Bis (benzimidazole) derivatives serving as potassium blocking agents |
| MA26659A1 (fr) | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
| EP1178977B1 (en) | 1999-05-12 | 2005-06-01 | Neurosearch A/S | Ion channel modulating agents |
| EP1309594B1 (fr) | 2000-08-08 | 2004-12-15 | Sanofi-Aventis | Derives de benzimidazole, leur preparation et leur application en therapeutique |
| EP1363624A2 (en) | 2001-02-20 | 2003-11-26 | Bristol-Myers Squibb Company | Fluoro oxindole derivatives as modulators of kcnq potassium channels |
| DE10135050A1 (de) | 2001-07-09 | 2003-02-06 | Schering Ag | 1-Ary1-2-N-, S- oder O-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| EP1511744A4 (en) | 2002-05-13 | 2009-10-21 | Icagen Inc | Bis-benzimidazoles and related compounds as potassium channel modulators |
-
2006
- 2006-01-10 EP EP06701206A patent/EP1838306B1/en not_active Expired - Lifetime
- 2006-01-10 US US11/795,018 patent/US7842817B2/en not_active Expired - Fee Related
- 2006-01-10 WO PCT/EP2006/050108 patent/WO2006074991A1/en not_active Ceased
- 2006-01-10 EP EP10182012A patent/EP2319512A1/en not_active Withdrawn
- 2006-01-10 JP JP2007549905A patent/JP2008526815A/ja not_active Abandoned
- 2006-01-10 DE DE602006018255T patent/DE602006018255D1/de not_active Expired - Lifetime
- 2006-01-10 AT AT06701206T patent/ATE488235T1/de not_active IP Right Cessation
-
2010
- 2010-07-08 US US12/832,343 patent/US20100280087A1/en not_active Abandoned
- 2010-10-21 US US12/909,362 patent/US20110034527A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526815A5 (https=) | ||
| JP2009519995A5 (https=) | ||
| US7528260B2 (en) | Method for preparing N-phenylpyrazole-1-carboxamides | |
| CN1080260C (zh) | 取代的吲哚衍生物以及它们作为iv型磷酸二酯酶(pde)和肿瘤坏死因子(tnf)抑制剂的用途 | |
| JP2008543915A5 (https=) | ||
| US7858804B2 (en) | Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof | |
| US20110034527A1 (en) | Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | |
| JP2009024025A (ja) | テモゾロミドおよびアナログの合成 | |
| CN1227555A (zh) | 细胞因子生成抑制剂、三氮䓬化合物及其中间体 | |
| CA2864517A1 (en) | Processes for the preparation of (s)-1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethylamine | |
| JP2008534472A5 (https=) | ||
| CN1419546A (zh) | 具有cb1－拮抗活性的4,5－二氢－1h－吡唑衍生物 | |
| IL235097A (en) | History of insulin-2 and as protein kinase inhibitors | |
| CN102036983B (zh) | 制备5-(2-氨基-嘧啶-4-基)-2-芳基-1h-吡咯-3-甲酰胺的方法 | |
| US20210163484A1 (en) | Method for synthesizing diversely substituted purines | |
| JP2009542602A5 (https=) | ||
| JP2013544797A5 (https=) | ||
| JP2010502674A5 (https=) | ||
| WO2014060908A1 (en) | Improved process for preparation of revaprazan hydrochloride | |
| CN1235967A (zh) | 咔唑酮衍生物 | |
| CN1511149A (zh) | 2-硫-取代咪唑衍生物及其药学用途 | |
| JP2010509249A5 (https=) | ||
| JP2009511548A5 (https=) | ||
| JP2009518359A5 (https=) | ||
| CN1261414C (zh) | 作为单胺氧化酶(mao－b)抑制剂的吡啶酰氨基衍生物 |